In T-NEPC patients, poorly differentiated neuroendocrine carcinoma are more prone to AR and PSA negative expression than prostate adenocarcinoma with neuroendocrine differentiation(P<0.001), there was no significant difference in clinicopathological features between prostate adenocarcinoma with diffuse neuroendocrine differentiation and prostate adenocarcinoma with focal neuroendocrine differentiation except AR positive(P = 0.034) (Table 2). This evidence concerns the gene AR and neuroendocrine carcinoma.